secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2025-05-02T23:59:59+00:00
Accession:  0000950170-25-062733
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 5.03, 3.02, 3.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tivic Health enters up to $8.4M Series B Preferred financing with Helena Global
-------------------------------------------------------------------------------

- Up to $8.4M from sale of Series B Non-Voting Convertible Preferred at $1,000/share plus warrants for common stock.
- Six tranche closings: initial $700k, then $700k, then $1.75M each for four more; warrants cover 30% of underlying common.
- Series B Preferred: 10% cumulative annual dividend, convertible at 90% of 5-day VWAP (floor $1.294).
- Registration rights: Company to file resale registration statement within 15 days for conversion and warrant shares.
- Stockholder approval required for second tranche and beyond; Exchange Cap of 19.99% of outstanding common.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025062733/0000950170-25-062733-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000095017025062733/tivc-20250429.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-062733

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer